ACR urges the FTC to thoroughly examine the impact of pharmacy benefit managers on prescription drug costs and access for people living with rheumatic disease
In comments submitted to the Federal Trade Commission (FTC), the American College of Rheumatology (ACR) urged the agency to address Pharmacy Benefit Manager (PBM) business practices that drive up costs… read more.
